本次会议为期三天，设置十余个分会场，涵盖神经外科、神经内科、脊髓脊柱外科、重症与创伤、麻醉 与疼痛、神经护理等多个亚专业领域，聚焦"神经肿瘤多学科协作诊疗""脑血管病介入治疗新进展""癫 痫外科治疗策略优化""脑机接口临床转化"等前沿议题。 会上，和泽启元（北京）科技有限公司还与首都医科大学三博脑科医院举行了战略合作签约仪式。三博 脑科董事长张阳表示，未来，三博脑科将会成立脑机接口与脑科学相关的投资平台、科研平台和临床验 证平台。 校对 赵琳 新京报讯（记者张兆慧）12月19日至21日，王忠诚院士百年诞辰学术会议暨第十八届三博神经科学学术 会议在北京召开。本次大会由王忠诚医学基金会、北京市神经外科研究所、首都医科大学附属北京天坛 医院、首都医科大学三博脑科医院联合主办，以"传承，创新，使命，共赢"为主题，汇聚国内神经科学 领域专家学者，通过学术研讨、成果交流等形式，缅怀医学前辈，共谋学科发展。 作为我国神经外科事业的开拓者和奠基人，王忠诚院士的一生是忠于医学、追求卓越的一生。他从抗美 援朝战场投身生命事业，开创中国脑血管造影技术，攻克脑干肿瘤等手术禁区，创办北京天坛医院与北 京市神经外科研究所，将毕生心血倾注 ...

以下文章来源于追问nextquestion ，作者追问 追问nextquestion . 科研就是不断探索问题的边界 要点速览： · 本文记录了8位顶尖神经科学家将大模型等AI工具纳入核心工作的具体场景，覆盖了细胞图谱绘制、文献分 析、数据处理、实验指导、代码生成、会议记录整理等多个场景。AI，已经成为科研不可或缺的"协作伙伴"。 · 核心应用聚焦六大方向：包括生成无偏大脑细胞图谱 （如CellTransformer模型） 、辅助非英语母语研究者提升文 本与编码效率、预测神经科学研究结果及复现可能性 （如BrainGPT项目） 、开发神经数据探索可视化工具、指 导疾病相关分子机制实验、快速提取文献结构化信息 （如MetaBeeAI） 。 那么，在神经科学——这个探索人类心智前沿的领域里，这一切是如何具体发生的？下面，八位顶尖的神 经科学家将为我们分享他们与这位"新同事"共事的独家故事。 Reza Abbasi-Asl：用Transformer 绘制无偏的大脑细胞地图 Reza Abbasi-Asl · AI主要承担大规模数据处理、重复劳动、初步分析等任务，人类研究者负责结果验证、错误纠正、深度解读及 关键决策 ...

Investment Rating - The report maintains an investment rating of "Outperform" for the brain-computer interface (BCI) industry [1] Core Insights - Continuous policy support is evident, with the Ministry of Industry and Information Technology and six other departments releasing implementation opinions to promote BCI innovation [2] - Significant technological and clinical breakthroughs have been achieved, including China's first invasive clinical trial for BCI technology [2] - The global BCI market is projected to exceed $10 billion, with a compound annual growth rate (CAGR) of over 13% from 2019 to 2023 [2] Summary by Sections What is Brain-Computer Interface? - BCI is defined as a communication system that establishes a direct connection between the brain and external devices, enabling interaction through brain wave recognition [7][10] - The technology is expected to revolutionize medical rehabilitation, assistive communication, and intelligent control [7] Why is BCI at a Critical Turning Point for Industrialization? - Policy support has intensified, with a clear roadmap for BCI standardization and development outlined by various government bodies [35][41] - The industry is expected to see significant advancements in technology and clinical applications, with a focus on creating a robust ecosystem by 2030 [35][46] Investment Recommendations - Companies to watch include Sanbo Brain Science, Zhongke Information, Entropy Technology, and Yanshan Technology, which are involved in clinical applications or product development [2]

Group 1 - The competition in sportswear has evolved from fabric and design to human science and materials engineering, with the China International Import Expo (CIIE) serving as a platform for brands to showcase their R&D capabilities [2] - Nike launched its neuroscience-based footwear product, Nike Mind, which utilizes 22 independent foam balls in the sole to activate foot sensory receptors, enhancing athletes' focus and presence [2] - Research conducted by Nike's neuroscience team showed that wearing Nike Mind before competitions significantly increased alpha brain wave activity related to focus and relaxation, with the product expected to launch in January 2026 [2] Group 2 - The winter coat market faces challenges with down jackets being warm but ineffective in humid conditions, while traditional cotton jackets are lightweight but lose insulation quickly [3] - Uniqlo introduced a new air cotton jacket that uses hollow fibers to create stable air pockets, providing warmth comparable to down jackets while maintaining performance in 80% humidity and being machine washable [3] - Adidas showcased the 2026 World Cup jerseys for Germany, Argentina, Spain, and Italy, featuring CLIMACOOL technology for optimized breathability and comfort in varying climates [3] Group 3 - The luxury brand Kering set up an immersive experience at its booth with Apple Vision Pro headsets, allowing viewers to experience fashion shows they could not attend, featuring the first ready-to-wear collection designed by Pierpaolo Piccioli since his appointment [3]

Core Viewpoint - The eighth China International Import Expo (CIIE) showcased significant advancements in neuroscience, particularly highlighting the global Phase III clinical study of the innovative therapy bexicaserin for developmental epileptic encephalopathy (DEE) by the pharmaceutical company Lingbei, emphasizing the importance of the expo as a platform for global collaboration in healthcare [1][2][4]. Group 1: Company Developments - Lingbei has established itself as a key player in the treatment of rare neurological diseases in China, having launched six products since its establishment in 2007 and serving 74 million patients [2][8]. - The company is initiating three international multicenter Phase III clinical studies for bexicaserin in collaboration with several leading Chinese medical institutions, aiming to address the urgent need for effective treatments for DEE [3][4]. - Bexicaserin has received breakthrough therapy designation from both the FDA and China's National Medical Products Administration, highlighting its potential to significantly improve treatment options for DEE patients [4][6]. Group 2: Product Innovations - The new drug bexicaserin is a novel oral 5-HT2C receptor agonist designed to reduce drug-resistant seizures in DEE patients, showing promising efficacy and safety in preliminary clinical trials [3][4]. - Lingbei's migraine treatment, eptinezumab, has demonstrated significant efficacy in reducing the frequency of migraine attacks in Asian populations, addressing the unmet need for preventive treatment among the 130 million migraine sufferers in China [5][6]. Group 3: Strategic Initiatives - Lingbei invests 20% of its annual revenue (approximately 4 billion Danish kroner) into research and development, focusing 90% of its pipeline on rare neurological diseases and specialized neurological fields [7]. - The company has been actively involved in enhancing public awareness of neurological diseases and patient education, collaborating with various stakeholders to build a comprehensive brain health ecosystem in China [8][9]. - Lingbei aims to contribute to the "Healthy China 2030" initiative by developing transformative treatment solutions for neurological diseases through sustained R&D investment and local partnerships [9].

Core Viewpoint - The eighth China International Import Expo (CIIE) will be held from November 5 to 10, 2025, in Shanghai, where the global pharmaceutical company Lundbeck will showcase its innovative therapies for developmental epileptic encephalopathy (DEE) and share advancements in migraine preventive treatment, emphasizing its commitment to making innovative therapies accessible to more patients in China [1][3]. Group 1: Company Initiatives - Lundbeck's General Manager for China, Zhang Yifan, highlighted the CIIE as a significant platform for deepening local cooperation and promoting advancements in neuroscience, aiming to raise awareness of the urgent needs of rare disease patients and the importance of migraine preventive treatment [3][4]. - The company has invested 20% of its annual revenue (approximately 4 billion Danish Kroner) into research and development, with 90% of its R&D pipeline focused on rare neurological diseases and specialized neurological treatments [4][5]. - Lundbeck has served over 74 million patients with brain diseases in China over the past 15 years, significantly accelerating clinical research across 19 provinces in the last five years [5][6]. Group 2: Clinical Research and Innovations - Lundbeck's investigational drug, bexicaserin, for treating DEE has initiated global Phase III clinical trials in China, addressing a critical unmet clinical need in this rare group of neurodevelopmental diseases [6][7]. - Bexicaserin has shown broad and lasting anti-seizure effects and has received breakthrough therapy designation from both the FDA and China's CDE, marking it as a potential "best-in-class" treatment for DEE [7][8]. - The company aims to improve migraine treatment in China, where approximately 130 million people are affected, and has made significant progress with its targeted CGRP monoclonal antibody, eptinezumab, which has shown efficacy in recent Phase III trials [7][8].

Core Insights - The article discusses the views of Matthew Cobb, a professor of zoology and neuroscience, on the differences between AI and the human brain, emphasizing that AI lacks true creativity and understanding [4][13]. Group 1: AI vs Human Brain - Cobb highlights that AI and the human brain are fundamentally different systems, with the former being a product of human engineering and the latter being a result of billions of years of evolution [5][7]. - The initial design of computers was inspired by the brain's neural connections, but it was soon realized that the brain does not operate like a digital system [6][7]. Group 2: AI's Role in Neuroscience - AI is expected to change how neuroscientists process vast amounts of data, helping to identify patterns that are not visible to the human eye [8][9]. - Despite its utility in data analysis, Cobb asserts that AI cannot serve as a model for understanding the complexities of the brain [9][10]. Group 3: Creativity and AI - Cobb argues that no AI system has produced anything genuinely creative, as they only generate outputs based on existing data and patterns [13][14]. - He emphasizes that while AI can enhance efficiency in certain tasks, it does not possess true understanding or the ability to create novel concepts [14][15]. Group 4: Human Connection in Caregiving - Cobb expresses a preference for human caregivers over machines, highlighting the importance of emotional connections in caregiving roles [16][17]. - He points out that many essential jobs, particularly in caregiving, cannot be replaced by machines, and stresses the need for better support and recognition for human caregivers [17][18].

Core Insights - The conversation with Matthew Cobb highlights the ongoing mystery surrounding the human brain and the limitations of current scientific understanding [3][6][8] - Cobb emphasizes the evolution of metaphors used to understand the brain, reflecting changes in technology and societal views [4][5] - The discussion also critiques the notion of artificial intelligence (AI) mimicking human consciousness, asserting that AI is a powerful tool but not a reflection of human thought [9][10] Group 1: Understanding the Brain - Cobb argues that humanity fundamentally does not understand how the brain operates, which is a central theme of his book "The Idea of the Brain" [6][7] - He recounts the historical metaphors used to describe the brain, from hydraulic systems to computers, illustrating the evolving nature of scientific understanding [4][5] - The complexity of the brain is highlighted, with Cobb noting that even simple organisms like fruit flies have neural mechanisms that remain poorly understood [8] Group 2: Artificial Intelligence Perspectives - Cobb identifies himself as part of the "AI skeptics," believing that while AI can perform specific tasks effectively, it does not possess consciousness [9][10] - He critiques the belief that increasing the scale of AI models will lead to human-like intelligence, arguing that this notion is fundamentally flawed [9] - The potential dangers of over-reliance on AI are discussed, particularly in contexts where AI-generated content is accepted without verification, leading to significant risks [10][12]

Core Insights - The article discusses the perspectives of the new generation on AI and its integration into their interests, professions, and future plans, as presented during the NEX-T Summit 2025 held at Stanford University [3][4]. Group 1: Event Overview - The NEX-T Summit 2025, themed "New Era of X-Tech," gathered over 400 entrepreneurs, investors, scientists, and policymakers to explore the impact of technology and capital on society [3]. - The summit featured a Youth Board aimed at inspiring leadership among the Asian youth and promoting innovation in the AI era [3]. Group 2: Panel Discussion Highlights - The roundtable discussion, moderated by Frances Sun, included four young guests from diverse educational backgrounds, sharing their insights on AI's role in their lives and studies [4][5]. - The participants discussed various applications of AI, their concerns about its implications, and the essential skills young people should develop in the AI age [4][5]. Group 3: Individual Perspectives - Elaine Du emphasized using AI for cultural preservation, highlighting her startup project that combines AI with traditional craftsmanship to document and protect cultural heritage [5][6]. - Tom Yuan shared his interdisciplinary approach, combining computer science and philosophy, and discussed the evolving role of AI in programming and software engineering [8][9]. - Cindy Ren focused on AI's application in neuroscience, proposing the use of deep learning to identify disease patterns and advocating for AI in educational equity [11][12]. - Catherine Chen illustrated AI's integration into her daily life and academic projects, stressing the importance of emotional management for young people in navigating challenges [16][17]. Group 4: Concerns and Aspirations - Concerns raised by the panelists included the potential for AI to exacerbate the digital divide, ethical issues surrounding AI in genetics, and the challenge of distinguishing AI-generated content from human-created works [6][10][13]. - Aspirations included using AI to combat poverty, reduce warfare, and improve healthcare outcomes, with a focus on extending healthy lifespans rather than pursuing immortality [7][14][18].

Core Insights - The rise of Brain-Machine Interfaces (BMI) is becoming a competitive field in Silicon Valley, with companies like Merge Labs and Neuralink leading the charge in innovative technologies [1][40] - Merge Labs, co-founded by Sam Altman, aims to compete with Neuralink by utilizing gene editing and ultrasound technology for non-invasive brain activity decoding [1][40] - The ultrasound BMI technology offers a new approach by reading blood flow signals non-invasively, contrasting with Neuralink's invasive electrode method [1][40] Group 1: Industry Evolution - The concept of BMIs has been around since the 1970s, but significant advancements have occurred in the last decade, with companies like Neuralink emerging [4][12] - Traditional electrical BMIs require electrodes to be implanted in the brain, which can be invasive and limited in scope [4][12] - The complexity of the brain, with its 86 billion neurons, necessitates a more holistic approach to decoding brain activity rather than focusing on isolated regions [5][6] Group 2: Ultrasound BMI Advantages - Ultrasound BMIs can cover a larger area of the brain, potentially imaging 25% of the brain volume compared to Neuralink's 0.13% coverage [17][20] - The time resolution of ultrasound technology is significantly better than fMRI, allowing for near real-time monitoring of blood flow signals [21][22] - Ultrasound BMIs are considered safer as they can be non-invasive, avoiding the risks associated with breaking the dura mater [26][49] Group 3: Clinical Applications - Current applications for ultrasound BMIs include chronic pain management, stroke rehabilitation, and potentially Alzheimer's treatment [32][33] - The technology aims to modulate neural activity through focused ultrasound, which can suppress overactive neurons associated with pain [24][25] - Future applications may extend to mental health disorders, such as depression and anxiety, by targeting specific brain regions [36][38] Group 4: Competitive Landscape - Several companies are emerging in the ultrasound BMI space, including Spire, Nudge, and Forest Neurotech, each focusing on different clinical applications [40][41] - Merge Labs is positioned as a significant player, with a focus on integrating gene therapy with ultrasound technology [40][45] - The competitive landscape indicates a growing interest and investment in non-invasive brain technologies, with potential for rapid advancements in clinical applications [40][41]